Patents by Inventor Peter Muench

Peter Muench has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220220158
    Abstract: The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 ?-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.
    Type: Application
    Filed: March 28, 2022
    Publication date: July 14, 2022
    Inventors: Elke Faatz, Alexander Riedel, Christian Scholz, Peter Muench, Gloria Tabares, Mario Gloeck, Silke Luebcke, Juliane Benz
  • Patent number: 11319351
    Abstract: The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 ß-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: May 3, 2022
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Alexander Riedel, Christian Scholz, Peter Muench, Gloria Tabares, Mario Gloeck, Silke Luebcke, Juliane Benz
  • Patent number: 11312750
    Abstract: The disclosure concerns a polypeptide suitable for detecting antibodies against Zika virus in an isolated biological sample having a Zika virus NS1 wing domain specific amino acid sequence and variants thereof, wherein no further Zika virus specific amino acid sequences are present in the polypeptide. This polypeptide does not immunologically cross-react with antibodies raised against structurally related antigens from tick-borne encephalitis virus, Dengue virus 1-4, West Nile virus, yellow fever virus or Japanese encephalitis virus, but immunologically reacts with antibodies raised against full length Zika virus NS1 antigen. Also disclosed is a method of producing a soluble and immunoreactive Zika virus NS1 polypeptide as well as methods and kits for detecting antibodies specific for Zika virus in an isolated sample.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: April 26, 2022
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Mario Gloeck, Peter Muench, Alexander Riedel, Christian Scholz, Gloria Tabares
  • Patent number: 11245156
    Abstract: A degassing unit for an electronics housing has a base body to be connected fluid-tightly to a rim of a pressure compensation opening of the electronics housing. The base body has a gas passage opening covered by a semipermeable membrane that enables passage of gaseous media but prevents passage of liquid and solids. A fluid-permeable protective screen with screen openings is arranged at an inner side of the base body across the gas passage opening. The base body has a thread engagement region for screw-connecting the degassing unit to the electronics housing. The protective screen has a screw through opening aligned with the thread engagement region of the base body. At the screw through opening, a thread engagement region of the protective screen is provided that fixes the protective screen by a threaded fastening element immediately relative to the electronics housing in a mounted state of the degassing unit.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: February 8, 2022
    Assignee: MANN+HUMMEL GmbH
    Inventors: Robert Zbiral, Peter Muench
  • Publication number: 20210349090
    Abstract: The present description relates to a Corona antigen having a Corona nucleocapsid specific amino acid sequence, compositions, and reagent kits having the same and methods of producing it. Also encompassed are methods of detecting anti-Corona antibodies in samples using the Corona antigen, and methods of differential diagnosis of an immune response in a patient due to natural Corona infection or due to vaccination against Corona.
    Type: Application
    Filed: May 6, 2020
    Publication date: November 11, 2021
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Alexander Riedel, Christian Scholz, Peter Muench, Juliane Benz, Markus Eckl, Frederik Baumkoetter
  • Publication number: 20210333277
    Abstract: The present invention relates to a Corona antigen comprising a Corona nucleocapsid specific amino acid sequence, compositions, and reagent kits comprising the same and methods of producing it. Also encompassed are methods of detecting anti-Corona antibodies in samples using said Corona antigen, and methods of differential diagnosis of an immune response in a patient due to natural Corona infection or due to vaccination against Corona.
    Type: Application
    Filed: April 23, 2020
    Publication date: October 28, 2021
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Alexander Riedel, Christian Scholz, Peter Muench, Juliane Benz, Markus Eckl, Frederik Baumkoetter
  • Patent number: 11150247
    Abstract: The present disclosure relates to a method for detecting a core polypeptide of a hepatitis C virus (HCV) in a sample from a subject involving (a) contacting said sample with a base and with a surfactant having a cationic detergent, and (b) detecting a core polypeptide of the HCV in the sample. The present invention further relates to a method for pre-processing a sample from a subject for detection of HCV, involving contacting the sample with a base and with a surfactant having a cationic detergent; and to a pre-processing reagent for detecting HCV in a sample, having a base and a surfactant including a cationic detergent, wherein the surfactant also has a nonionic detergent. Moreover, the present disclosure further relates to kits, uses, and devices related to the methods disclosed.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: October 19, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Ralf Bollhagen, Barbara Upmeier, Toralf Zarnt, Peter Muench, Manfred Ginter
  • Patent number: 10891266
    Abstract: A user virtual file system within a hierarchical storage system performs file handling. A user virtual file system scans, reads and analyses data or user behavior to create or modify at least one rule or metadata. The user virtual file system identifies logical or temporal relationships of files based on the at least one rule or the metadata. The user virtual file system groups identified related files in the at least one container. The user virtual file system moves the at least one container to different tiers of storage based on the at least one rule or the metadata.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: January 12, 2021
    Assignee: International Business Machines Corporation
    Inventors: Hans-Guenter Kraemer, Peter Muench, Rolf Schaefer, Norbert J. Schuld
  • Publication number: 20200388807
    Abstract: A degassing unit for an electronics housing has a base body to be connected fluid-tightly to a rim of a pressure compensation opening of the electronics housing. The base body has a gas passage opening covered by a semipermeable membrane that enables passage of gaseous media but prevents passage of liquid and solids. A fluid-permeable protective screen with screen openings is arranged at an inner side of the base body across the gas passage opening. The base body has a thread engagement region for screw-connecting the degassing unit to the electronics housing. The protective screen has a screw through opening aligned with the thread engagement region of the base body. At the screw through opening, a thread engagement region of the protective screen is provided that fixes the protective screen by a threaded fastening element immediately relative to the electronics housing in a mounted state of the degassing unit.
    Type: Application
    Filed: May 13, 2020
    Publication date: December 10, 2020
    Inventors: Robert Zbiral, Peter Muench
  • Publication number: 20200048313
    Abstract: The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 ß-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.
    Type: Application
    Filed: October 25, 2019
    Publication date: February 13, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Alexander Riedel, Christian Scholz, Peter Muench, Gloria Tabares, Mario Gloeck, Silke Luebcke, Juliane Benz
  • Publication number: 20200048312
    Abstract: The disclosure concerns a polypeptide suitable for detecting antibodies against Zika virus in an isolated biological sample having a Zika virus NS1 wing domain specific amino acid sequence and variants thereof, wherein no further Zika virus specific amino acid sequences are present in the polypeptide. This polypeptide does not immunologically cross-react with antibodies raised against structurally related antigens from tick-borne encephalitis virus, Dengue virus 1-4, West Nile virus, yellow fever virus or Japanese encephalitis virus, but immunologically reacts with antibodies raised against full length Zika virus NS1 antigen. Also disclosed is a method of producing a soluble and immunoreactive Zika virus NS1 polypeptide as well as methods and kits for detecting antibodies specific for Zika virus in an isolated sample.
    Type: Application
    Filed: October 25, 2019
    Publication date: February 13, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Mario Gloeck, Peter Muench, Alexander Riedel, Christian Scholz, Gloria Tabares
  • Publication number: 20200033342
    Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.
    Type: Application
    Filed: September 20, 2019
    Publication date: January 30, 2020
    Inventors: Elke Faatz, Christian Scholz, Peter Muench
  • Patent number: 10466242
    Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 5, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Christian Scholz, Peter Muench
  • Publication number: 20190086412
    Abstract: The present disclosure relates to a method for detecting a core polypeptide of a hepatitis C virus (HCV) in a sample from a subject involving (a) contacting said sample with a base and with a surfactant having a cationic detergent, and (b) detecting a core polypeptide of the HCV in the sample. The present invention further relates to a method for pre-processing a sample from a subject for detection of HCV, involving contacting the sample with a base and with a surfactant having a cationic detergent; and to a pre-processing reagent for detecting HCV in a sample, having a base and a surfactant including a cationic detergent, wherein the surfactant also has a nonionic detergent. Moreover, the present disclosure further relates to kits, uses, and devices related to the methods disclosed.
    Type: Application
    Filed: November 29, 2018
    Publication date: March 21, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Ralf Bollhagen, Barbara Upmeier, Toralf Zarnt, Peter Muench, Manfred Ginter
  • Patent number: 10094828
    Abstract: The present invention concerns a composition of polypeptides suitable for detecting antibodies against Trypanosoma cruzi (T. cruzi) in an isolated biological sample consisting of three polypeptides 1F8, JL7 and Cruzipain. A method of producing a soluble and immunoreactive composition of polypeptides suitable for detecting antibodies against T. cruzi using said composition of polypeptides is also part of the invention. Moreover, the invention concerns a method for detecting antibodies specific for T. cruzi in an isolated sample wherein a composition of said T. cruzi polypeptides is used as well as a reagent kit comprising said composition of T. cruzi polypeptides.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: October 9, 2018
    Inventors: Peter Muench, Dieter Roessler, Christian Scholz, Barbara Upmeier, Toralf Zarnt
  • Publication number: 20180164314
    Abstract: Disclosed is a method for detecting a capsid polypeptide of a non-enveloped virus in a sample from a subject which includes (a) contacting the sample with a base, and (b) detecting a capsid polypeptide of the virus in the sample. Moreover, the present disclosure relates to a method for pre-processing a sample from a subject for detection of a virus, including contacting the sample with a base. Moreover, the present disclosure relates to kits, uses and devices related to these methods.
    Type: Application
    Filed: February 9, 2018
    Publication date: June 14, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Peter Muench, Mirko Ritter, Gloria Tabares
  • Publication number: 20170248597
    Abstract: The present invention concerns a composition of polypeptides suitable for detecting antibodies against Trypanosoma cruzi (T. cruzi) in an isolated biological sample consisting of three polypeptides 1F8, JL7 and Cruzipain. A method of producing a soluble and immunoreactive composition of polypeptides suitable for detecting antibodies against T. cruzi using said composition of polypeptides is also part of the invention. Moreover, the invention concerns a method for detecting antibodies specific for T. cruzi in an isolated sample wherein a composition of said T. cruzi polypeptides is used as well as a reagent kit comprising said composition of T. cruzi polypeptides.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 31, 2017
    Inventors: Peter Muench, Dieter Roessler, Christian Scholz, Barbara Upmeier, Toralf Zarnt
  • Publication number: 20170184591
    Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.
    Type: Application
    Filed: August 25, 2016
    Publication date: June 29, 2017
    Inventors: Elke Faatz, Christian Scholz, Peter Muench
  • Patent number: 9465407
    Abstract: A user interface of a controller has multiple touch-sensitive input transducers, e.g., capacitive pads. The pads are dynamically indicated: When any given touch sensitive input device is needed for input at a given step of the programming operation, an associated light source illuminates that input device so it is visible to the user. Those touch-panel input devices not needed for that are left unilluminated, and the microprocessor ignores any input from those input devices. At each step of the operation or programming of the controller, only those input transducers for the inputs that are permitted or relevant to that state are indicated. Correspondingly, only the inputs that are generated by actuating the input transducers for the valid (i.e., permitted or relevant) inputs results in a change in the state of the program in the microprocessor.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: October 11, 2016
    Assignee: ICM CONTROLS CORPORATION
    Inventors: Andrew S. Kadah, Weidong Pan, Hollis Jordan Gmyr, James H. Ritchie, Eric Christopher Wood, Benjamin A. Freer, Michael Peter Muench, Kevin Jobsky
  • Publication number: 20150325869
    Abstract: A humidifier is provided with a housing and at least one water-permeable membrane arranged in the housing and provided with first and second opposed sides. A first gas stream having a first moisture contents is guided on the first opposed side and a second gas stream having a second moisture contents is guided on the second opposed side through the humidifier. The first moisture contents is higher than the second moisture contents. The at least one water-permeable membrane is folded and has folds.
    Type: Application
    Filed: May 1, 2015
    Publication date: November 12, 2015
    Inventors: Michael Fasold, Ralf Werner, Egon Ellmer, Mathias Weiss, Michael Maier, Patricie Merkert, Dirk Eberspaecher, Peter Muench, Andreas Kloz, Thomas Tschech, Oliver Wiesner, Andreas Epp, Reiner Bulling, Volker Kuemmerling, Marcel Mayer